|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-4-27
|
|
pubmed:abstractText |
Although erlotinib, an orally active and selective tyrosine kinase inhibitor of epidermal growth factor receptor, is mainly metabolized in the liver, its effectiveness and safety for patients with chronic renal failure (CRF) undergoing hemodialysis (HD) has not been reported. Thus, we investigated the pharmacokinetics (PK) of erlotinib and its active metabolite OSI-420 in such patients with nonsmall cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:FujitaShiroS,
pubmed-author:FukudoMasahideM,
pubmed-author:IkemiYasuakiY,
pubmed-author:InuiKen-IchiK,
pubmed-author:IrisaKaoruK,
pubmed-author:KimYoung HakYH,
pubmed-author:MasagoKatsuhiroK,
pubmed-author:MioTadashiT,
pubmed-author:MishimaMichiakiM,
pubmed-author:SakamoriYuichiY,
pubmed-author:TeradaTomohiroT,
pubmed-author:TogashiYosukeY
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
601-5
|
|
pubmed:meshHeading |
pubmed-meshheading:20234322-Adenocarcinoma,
pubmed-meshheading:20234322-Aged,
pubmed-meshheading:20234322-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20234322-Carcinoma, Squamous Cell,
pubmed-meshheading:20234322-Drug Therapy, Combination,
pubmed-meshheading:20234322-Humans,
pubmed-meshheading:20234322-Kidney Failure, Chronic,
pubmed-meshheading:20234322-Lung Neoplasms,
pubmed-meshheading:20234322-Male,
pubmed-meshheading:20234322-Protein Kinase Inhibitors,
pubmed-meshheading:20234322-Quinazolines,
pubmed-meshheading:20234322-Receptor, Epidermal Growth Factor,
pubmed-meshheading:20234322-Renal Dialysis,
pubmed-meshheading:20234322-Tissue Distribution,
pubmed-meshheading:20234322-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
|
|
pubmed:affiliation |
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
